50 Participants Needed

HyperSight CBCT Imaging for Cancer

Recruiting at 2 trial locations
SD
Overseen BySean Davidson
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Varian, a Siemens Healthineers Company
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on imaging technology, so it's unlikely to require changes to your medication, but you should confirm with the study team.

What data supports the effectiveness of the treatment HyperSight CBCT Imaging for Cancer?

Research shows that cone-beam computed tomography (CBCT) can help improve the accuracy of radiation therapy by better targeting the cancerous area, as seen in studies with esophageal and head-neck cancers. This suggests that HyperSight CBCT might also be effective in improving cancer treatment by reducing exposure to healthy tissues.12345

Is HyperSight CBCT imaging safe for humans?

Research on cone-beam computed tomography (CBCT) shows that while it is useful for precise imaging, it does expose patients to radiation, which can increase the risk of secondary cancer. Efforts are being made to reduce this radiation exposure through modified protocols and shielding.678910

How is HyperSight CBCT Imaging different from other cancer treatments?

HyperSight CBCT Imaging is unique because it offers rapid imaging in just 6 seconds with enhanced image quality, which helps in better visualization and treatment planning for cancer compared to traditional imaging methods. This technology allows for more precise targeting of tumors during treatment, potentially improving outcomes.1112131415

What is the purpose of this trial?

Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.This study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.The goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.

Eligibility Criteria

This trial is for cancer patients with conditions like breast, lung, genitourinary cancers, hepatocellular carcinoma, gastrointestinal cancer, and head and neck cancers. Participants should be undergoing radiation therapy and able to undergo additional CBCT imaging without health risks.

Inclusion Criteria

My radiation therapy plan includes a CBCT scan for treatment guidance.
I am undergoing radiation therapy for cancer in my head, neck, chest, liver, breast, genital organs, or digestive system.

Exclusion Criteria

I use a wheelchair for mobility.
Patient has a life expectancy <3 months
I need help with my daily activities due to my health condition.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Radiation Treatment

Participants undergo radiation treatment using HyperSight CBCT to evaluate image quality and its impact on treatment delivery

9 weeks
Daily visits for radiation treatment

Follow-up

Participants are monitored for safety and effectiveness after radiation treatment

4 weeks

Treatment Details

Interventions

  • HyperSight CBCT
Trial Overview The study compares a new CBCT imaging technology called HyperSight to conventional CBCT in terms of image quality. It aims to see if HyperSight can improve the accuracy of radiation treatment delivery by providing clearer images for various tasks beyond patient positioning.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging ArmExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Varian, a Siemens Healthineers Company

Lead Sponsor

Trials
35
Recruited
7,200+

Findings from Research

In a study involving 20 breast cancer patients, cone-beam computed tomography (CBCT) was found to significantly reduce setup uncertainties compared to electronic portal imaging devices (EPID), with EPID underestimating setup errors by 20% to 50%.
The analysis revealed that while both imaging methods showed differences in measuring setup errors, CBCT provided more accurate measurements of bony anatomy, leading to better alignment during treatment.
Breast patient setup error assessment: comparison of electronic portal image devices and cone-beam computed tomography matching results.Topolnjak, R., Sonke, JJ., Nijkamp, J., et al.[2022]
Using cone beam computed tomography (CBCT) imaging in the first week of radiotherapy allows for the creation of a patient-specific planning target volume (PTV), which can lead to more precise treatment targeting.
The adaptive radiotherapy plan significantly reduced radiation exposure to the lungs and heart, with the lung dose decreasing from 15.6 Gy to 10.2 Gy and the heart mean dose from 26.9 Gy to 20.7 Gy, demonstrating improved safety for patients undergoing treatment for esophageal carcinoma.
Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer.Hawkins, MA., Brooks, C., Hansen, VN., et al.[2016]
Reducing the radiographic field of view (FOV) in cone beam computed tomography (CBCT) does not enhance the accuracy of implant planning for single posterior missing teeth, suggesting that a full arch view may be unnecessary in these cases.
However, caution is advised when using a reduced FOV in scenarios with multiple missing teeth or radiographic artifacts, as these conditions can lead to significant discrepancies in alignment, particularly with maximum deviations observed up to 1.44 mm.
Impact of radiographic field-of-view volume on alignment accuracy during virtual implant planning: A noninterventional retrospective pilot study.Pieralli, S., Beyer, C., Wesemann, C., et al.[2022]

References

Breast patient setup error assessment: comparison of electronic portal image devices and cone-beam computed tomography matching results. [2022]
Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. [2016]
Impact of radiographic field-of-view volume on alignment accuracy during virtual implant planning: A noninterventional retrospective pilot study. [2022]
Patient movement characteristics and the impact on CBCT image quality and interpretability. [2022]
Investigation of cone-beam CT image quality trade-off for image-guided radiation therapy. [2016]
Can modifying shielding, field of view, and exposure settings make the effective dose of a cone-beam computed tomography comparable to traditional radiographs used for orthodontic diagnosis? [2021]
Imaging doses for different CBCT protocols on the Halcyon 3.0 linear accelerator - TLD measurements in an anthropomorphic phantom. [2023]
An Investigation of the Feasibility and Utility of a Low-dose Cone-beam Computed Tomography Scan Protocol for Head and Neck Cancer Patients. [2019]
The frequency and nature of incidental findings in large-field cone beam computed tomography scans of an orthodontic sample. [2022]
CBCTs in a Swiss university dental clinic: a retrospective evaluation over 5 years with emphasis on radiation protection criteria. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Novel Technology Allowing Cone Beam Computed Tomography in 6 Seconds: A Patient Study of Comparative Image Quality. [2023]
12.United Statespubmed.ncbi.nlm.nih.gov
SU-E-J-08: Dependence of Imaging Dose on Image Quality of Free-Breathing 3DCBCT of Moving Tumors. [2019]
Optimal acquisition time to discriminate between breast cancer subtypes with contrast-enhanced cone-beam CT. [2021]
C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. [2021]
Essentials of maxillofacial cone beam computed tomography. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security